Advanced search×

Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells.

Yang Y Li, Ingo G H IG Schmidt-Wolf, Yan-Feng YF Wu, Shao-Liang SL Huang, Jing J Wei, Jianpei J Fang, Ke K Huang, and Dun-Hua DH Zhou

Audio, Transactions of the IRE Profession... 30(9):3493-9 (2010) PMID 20944128

The efficacy of various combinations of stem cell factor (SCF), FLT3 ligand, interleukin (IL)-2, IL-7 and IL-15 to induce and expand cord blood-derived cytokine-induced killer (CIK) cells was investigated. There were three treatment groups: group A: SCF combined with IL-2, IL-7 and IL-15; group B: SCF, FLT3 ligand combined with IL-2, IL-7 and IL-15, and group C: IL-2, IL-7 and IL-15, the control group. Proliferation rates of CD3(+)CD56(+) CIK cells and CD3(-)CD56(+) natural killer (NK) cells were highest in group B; expansion of CIK cells increased 796.1 ± 278.5-fold, and that of NK cells increased 36.6 ± 3.5-fold. All expanded cord blood-derived CIK/NK cells showed cytotoxic activity against the K562 cell line. Interestingly, the cytotoxicity of group A was highest and significantly higher than that of other groups. These protocols might provide an alternative choice for CIK/NK cell expansion.

Version: za2963e q8zab q8zbb q8zcf q8zd8 q8zeb q8zf2 q8zge

Similar articles you may find interesting…

  1. Life-prolonging effect of immunocell BAK (BRM-activated killer) therapy for advanced solid cancer patients: prognostic significance of serum...
    Takusaburo Ebina, Naoko Ogama, ... Noriko Isono

    Cancer Immunol Immunother 52(9):555-60 (2003) PMID 14627127

    We devised an innovative type of immunocell therapy called BRM (biological response modifier)-activated killer (BAK) therapy, which utilizes most of non-MHC (major histocompatibility complex) restricted lymphocytes, CD56+ cells including gammadelta T cells and NK cells. Peripheral blood lymphocytes...
  2. Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells.
    Weiyun Z Ai, Jing-Zhou Hou, ... Ronald Levy

    Int J Cancer 124(1):239-44 (2009) PMID 18814264 PMCID 2631275

    We investigated whether FL tumor B cells, as opposed to normal B cells, are unique in their ability to convert effector T cells into Treg. We found that tumor B cells alone, without artificial TCR stimulation, could induce conventional T cells to express FoxP3 and to acquire regulatory function. In...
    View PDF
  3. CD4^+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation
    Kavya K Rakhra, Pavan P Bachireddy, ... Dean W DW Felsher

    Cancer Cell 18(5):14 (2010) PMID 21035406 PMCID PMC2991103

    We show that an intact immune system, specifically CD4(+) T cells, is required for the induction of cellular senescence, shutdown of angiogenesis, and chemokine expression resulting in sustained tumor regression upon inactivation of the MYC or BCR-ABL oncogenes in mouse models of T cell acute lymp...
    View PDF